Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-290.44M |
| Operating Margin | 0.00% |
| Return on Equity | -134.30% |
| Return on Assets | -51.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.26 |
| Price-to-Book | 11.56 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $94.22M |
| Float | $67.65M |
| % Insiders | 1.65% |
| % Institutions | 104.25% |
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers.
Investors allege Replimune Group, Inc. told the market its RP1 resubmission was a complete response to the FDA's prior deficiency letter, while the agency's evidentiary standards for an "adequate and well-controlled" trial allegedly were never satisfied. NEW YORK, Sept.
Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval, yet allegedly omitted that the FDA had already told the Company its study design concerns were unresolved. NEW YORK, Sept.
Replimune shareholders who bought REPL stock between October 20, 2025 and April 10, 2026 retain specific rights under the federal securities laws after the FDA's rejection of the RP1 biologics license application allegedly erased more than 80% of the stock's Class Period value.
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers.
A chronology of Replimune's RP1 regulatory disclosures alleges that between October 20, 2025 and April 10, 2026, investors were told the FDA resubmission was on track while previously communicated study-design concerns allegedly remained unresolved. NEW YORK, Sept.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).
Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. NEW YORK, Sept.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on REPL and any ticker you trade — then tracks every position and per-strategy win rate.
